Nanomedicines for prostate cancer therapy: stimuli-responsive design and disease-specific applications.
Prostate cancer (PCa) remains a major malignancy among men and is clinically complicated by biological heterogeneity, treatment resistance and frequent bone metastasis. Current therapeutic strategies, including radical local treatment, androgen deprivation therapy, androgen receptor (AR) pathway inhibitors, chemotherap...